Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 396

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1C
Chunk 396
---
uant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized on the 31st day of March, 2025.

    bioAffinity
    Technologies, Inc.

    By:
    /s/
    Maria Zannes

    Maria
    Zannes

    Chief
    Executive Officer, President, and Director

Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

    Signature
     
    Title
     
    Date

    /s/
    Maria Zannes
     
    President,
    Chief Executive Officer, and Director
    (Principal
    Executive Officer)
     
    March
    31, 2025
  
    Maria
    Zannes

    /s/
    J. Michael Edwards
     
    Chief
    Financial Officer
     
    March
    31, 2025
  
    J.
    Michael Edwards
     
    (Principal
    Financial and Accounting Officer)

    /s/
    Steven Girgenti
     
    Executive
    Chairman and Director
     
    March
    31, 2025
  
    Steven
    Girgenti

    /s/
    Robert Anderson
     
    Director
     
    March
    31, 2025
  
    Robert
    Anderson

    /s/
    Stuart Diamond
     
    Director
     
    March
    31, 2025
  
    Stuart
    Diamond

    /s/
    Peter S. Knight
     
    Director
     
    March
    31, 2025
  
    Peter
    S. Knight

    /s/
    Gary Rubin 
     
    Director
     
    March
    31, 2025
  
    Gary
    Rubin

    /s/
    Roby Joyce, M.D.
     
    Director
     
    March
    31, 2025
  
    Roby
    Joyce

    /s/
    Jamie Platt
     
    Director
     
    March
    31, 2025
  
    Jamie
    Platt

 70 

bioAffinity
Technologies